{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:11:43Z","timestamp":1791983503668,"version":"4.4.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejca.2021.02.035","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T08:18:38Z","timestamp":1618474718000},"page":"134-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6561-1919","authenticated-orcid":false,"given":"Francesco","family":"Schettini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4160-3479","authenticated-orcid":false,"given":"Fabiola","family":"Giudici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6837-1938","authenticated-orcid":false,"given":"Ottavia","family":"Bernocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-3858","authenticated-orcid":false,"given":"Marianna","family":"Sirico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4971-1076","authenticated-orcid":false,"given":"Silvia P.","family":"Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariavittoria","family":"Locci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4668-4765","authenticated-orcid":false,"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.02.035_bib1","series-title":"Genetics of breast and gynecologic cancers (PDQ\u00ae) - health professional version","year":"2019"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.035_bib2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.ejca.2021.02.035_bib3","doi-asserted-by":"crossref","first-page":"R759","DOI":"10.1016\/S0960-9822(00)80005-6","article-title":"DNA double-strand break repair","volume":"9","author":"Featherstone","year":"1999","journal-title":"Curr Biol"},{"issue":"11","key":"10.1016\/j.ejca.2021.02.035_bib4","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.cdd.4400938","article-title":"DNA damage and apoptosis","volume":"8","author":"Wang","year":"2001","journal-title":"Cell Death Differ"},{"issue":"9","key":"10.1016\/j.ejca.2021.02.035_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc1431","article-title":"BRCA1 and BRCA2: 1994 and beyond","volume":"4","author":"Narod","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2021.02.035_bib6","unstructured":"Susan G. Komen foundation. Inherited genetic mutations."},{"issue":"4","key":"10.1016\/j.ejca.2021.02.035_bib7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.15406\/jcpcr.2019.10.00400","article-title":"Update on PARP inhibitor therapy for solid tumours","volume":"10","author":"Bayraktar","year":"2019","journal-title":"J Cancer Prev Curr Res"},{"issue":"4","key":"10.1016\/j.ejca.2021.02.035_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2021.02.035_bib9","first-page":"28","article-title":"Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications","volume":"7","author":"McClain","year":"2005","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"10.1016\/j.ejca.2021.02.035_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4986365","article-title":"BRCA mutations in prostate cancer: prognostic and predictive implications","author":"Messina","year":"2020","journal-title":"J Oncol"},{"key":"10.1016\/j.ejca.2021.02.035_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.gore.2019.07.007","article-title":"BRCA mutation in high grade epithelial ovarian cancers","volume":"29","author":"Manchana","year":"2019","journal-title":"Gynecol Oncol Rep"},{"issue":"6367","key":"10.1016\/j.ejca.2021.02.035_bib12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/356356a0","article-title":"Role of poly(ADP-ribose) formation in DNA repair","volume":"356","author":"Satoh","year":"1992","journal-title":"Nature"},{"issue":"6330","key":"10.1016\/j.ejca.2021.02.035_bib13","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"7035","key":"10.1016\/j.ejca.2021.02.035_bib14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.ejca.2021.02.035_bib15","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/j.ejca.2021.02.035_bib16","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.035_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/1541-7786.MCR-18-0138","article-title":"PARP1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow","volume":"17","author":"Hopkins","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2021.02.035_bib18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/annonc\/mdx505","article-title":"Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized phase II study","volume":"29","author":"Han","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.02.035_bib19","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2021.02.035_bib20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.02.035_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.035_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41416-018-0343-z","article-title":"A phase 2 randomised study of veliparib plus FOLFIRI\u00b1bevacizumab versus placebo plus FOLFIRI\u00b1bevacizumab in metastatic colorectal cancer","volume":"120","author":"Gorbunova","year":"2019","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2021.02.035_bib23","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.02.035_bib24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.18.00264","article-title":"Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study","volume":"37","author":"Owonikoko","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2021.02.035_bib25","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.02.035_bib26","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1158\/1078-0432.CCR-15-3069","article-title":"Randomized, placebo-controlled, phase II study of veliparib in combination with carboplatin and paclitaxel for advanced\/metastatic non-small cell lung cancer","volume":"23","author":"Ramalingam","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2021.02.035_bib27","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/annonc\/mdv308","article-title":"Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"9737","key":"10.1016\/j.ejca.2021.02.035_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet Lond Engl"},{"issue":"10106","key":"10.1016\/j.ejca.2021.02.035_bib29","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"25","key":"10.1016\/j.ejca.2021.02.035_bib30","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ejca.2021.02.035_bib31","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2021.02.035_bib32","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2021.02.035_bib33","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-14-2565","article-title":"Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer","volume":"21","author":"Kummar","year":"2015","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"15","key":"10.1016\/j.ejca.2021.02.035_bib34","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2021.02.035_bib35","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2021.02.035_bib36","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.02.035_bib37","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/annonc\/mdz018","article-title":"Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer","volume":"30","author":"Liu","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2021.02.035_bib38","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2021.02.035_bib39","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(19)30515-7","article-title":"Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2\/ENGOT-ov24): a randomised, phase 2, superiority trial","volume":"20","author":"Mirza","year":"2019","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2021.02.035_bib40","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2021.02.035_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2021.02.035_bib42","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial","volume":"38","author":"Penson","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2021.02.035_bib43","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.ejca.2021.02.035_bib44","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2021.02.035_bib45","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2021.02.035_bib46","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2021.02.035_bib47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.02.035_bib48","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6002","article-title":"Final overall survival (OS) results from SOLO2\/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation","volume":"38","author":"Poveda","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.02.035_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00570","article-title":"Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumours","author":"Vikas","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2021.02.035_bib50","series-title":"Clinical trial endpoints for the approval of cancer drugs and biologics","first-page":"19","year":"2018"},{"key":"10.1016\/j.ejca.2021.02.035_bib51","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2021.02.035_bib52","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","article-title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Di\u00e9ras","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2021.02.035_bib53","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2021.02.035_bib54","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.035_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"issue":"18","key":"10.1016\/j.ejca.2021.02.035_bib56","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/sim.1221","article-title":"A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials","volume":"21","author":"Baujat","year":"2002","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.035_bib57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.ejca.2021.02.035_bib58","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.ejca.2021.02.035_bib59","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2021.02.035_bib60","series-title":"A language and environment for statistical computing","year":"2017"},{"key":"10.1016\/j.ejca.2021.02.035_bib61","series-title":"Review manager (RevMan)","year":"2014"},{"key":"10.1016\/j.ejca.2021.02.035_bib62","unstructured":"Higgins J, Green S. Cochrane Handbook for systematic reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration."},{"issue":"5584","key":"10.1016\/j.ejca.2021.02.035_bib63","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2021.02.035_bib64","article-title":"Androgen receptor signaling in prostate cancer development and progression","author":"Lonergan","year":"2011","journal-title":"J Carcinog"},{"key":"10.1016\/j.ejca.2021.02.035_bib65","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3922-0","article-title":"Incidence of bone metastases in patients with solid tumours: analysis of oncology electronic medical records in the United States","author":"Hernandez","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2021.02.035_bib66","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination\u2013related gene mutations across multiple cancer types","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"7353","key":"10.1016\/j.ejca.2021.02.035_bib67","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2021.02.035_bib68","unstructured":"Myriad Genetics, Inc. Myriad myChoice\u00ae CDx description. Available at: https:\/\/myriad.com\/products-services\/precision-medicine\/mychoice-cdx\/. 2020."},{"key":"10.1016\/j.ejca.2021.02.035_bib69","series-title":"FoundationOne\u00aeCDx technical specifications","year":"2018"},{"issue":"47","key":"10.1016\/j.ejca.2021.02.035_bib70","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1038\/onc.2013.311","article-title":"A high-throughput screen identifies PARP1\/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer","volume":"32","author":"Postel-Vinay","year":"2013","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.ejca.2021.02.035_bib71","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2021.02.035_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107985","article-title":"The ubiquitin ligase TRIP12 limits PARP1 trapping and constrains PARP inhibitor efficiency","author":"Gatti","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.ejca.2021.02.035_bib73","unstructured":"FDA Approves Entrectinib for Tumours with NTRK Fusions - National Cancer Institute. [https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2019\/fda-entrectinib-ntrk-fusion]. ."},{"key":"10.1016\/j.ejca.2021.02.035_bib74","unstructured":"FDA approves pembrolizumab for first-line treatment of MSI-H\/dMMR colorectal cancer. [https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer]. ."},{"key":"10.1016\/j.ejca.2021.02.035_bib75","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CLEP.S242097","article-title":"Synthetic and external controls in clinical trials \u2013 a primer for researchers","volume":"12","author":"Thorlund","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.035_bib76","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"362","key":"10.1016\/j.ejca.2021.02.035_bib77","doi-asserted-by":"crossref","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.ejca.2021.02.035_bib78","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1111\/jcmm.14133","article-title":"PARP inhibitors in ovarian cancer: sensitivity prediction and resistance mechanisms","volume":"23","author":"Jiang","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/j.ejca.2021.02.035_bib79","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2018.09.048","article-title":"Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency","volume":"75","author":"Zafeiriou","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ejca.2021.02.035_bib80","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.molcel.2019.06.020","article-title":"Activation of PARP-1 by snoRNAs controls ribosome biogenesis and cell growth via the RNA helicase DDX21","volume":"75","author":"Kim","year":"2019","journal-title":"Mol Cell"},{"issue":"5","key":"10.1016\/j.ejca.2021.02.035_bib81","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ccr.2011.04.010","article-title":"Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer","volume":"19","author":"Brenner","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ejca.2021.02.035_bib82","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3892\/ijo.2015.3003","article-title":"The PARP inhibitor AZD2281 (Olaparib) induces autophagy\/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells","volume":"47","author":"Arun","year":"2015","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2021.02.035_bib83","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920944116","article-title":"PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers","author":"Lee","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2021.02.035_bib84","doi-asserted-by":"crossref","DOI":"10.1080\/23723556.2019.1585170","article-title":"Beyond DNA repair: the novel immunological potential of PARP inhibitors","author":"Chabanon","year":"2019","journal-title":"Mol Cell Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2021.02.035_bib85","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41416-018-0274-8","article-title":"Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes","volume":"119","author":"Hodgson","year":"2018","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2021.02.035_bib86","first-page":"1323","article-title":"PARP inhibition combined with immune checkpoint blockade in SCLC: oasis in an immune desert or mirage?","volume":"14","author":"Gay","year":"2019","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2021.02.035_bib87","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.02.035_bib88","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.106","article-title":"TOPACIO\/Keynote-162 (NCT02657889): a phase 1\/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)\u2014results from ROC cohort","volume":"36","author":"Konstantinopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.02.035_bib89","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/sim.1023","article-title":"Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head","volume":"21","author":"Berlin","year":"2002","journal-title":"Stat Med"},{"issue":"Suppl","key":"10.1016\/j.ejca.2021.02.035_bib90","article-title":"A framework for deciding if individual participant data are likely to be worthwhile. Abstracts of the 23rd Cochrane Colloquium, Vienna, Austria","volume":"10","author":"Tudur Smith","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ejca.2021.02.035_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003019","article-title":"Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: an observational study","volume":"17","author":"Tierney","year":"2020","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.ejca.2021.02.035_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000361","article-title":"Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis","volume":"3","author":"Poggio","year":"2018","journal-title":"ESMO Open"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2021.06.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492100143X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492100143X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T01:02:26Z","timestamp":1678669346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492100143X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":92,"alternative-id":["S095980492100143X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.02.035","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejca.2021.06.001","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}